within Pharmacolibrary.Drugs.ATC.L;

model L01EF02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.00036166666666666666,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1.09,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00855,
    Tlag           = 24.599999999999998,            
    Vdp             = 0.512,
    k12             = 116,
    k21             = 116
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EF02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ribociclib is an orally active, selective cyclin-dependent kinase (CDK) 4/6 inhibitor used for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. It is commonly used in combination with endocrine therapies, and is approved for use in multiple regions as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on data from adult patients with advanced breast cancer, both sexes, oral administration under fasting or fed state.</p><h4>References</h4><ol><li><p>Samant, TS, Yang, S, Miller, M, &amp; Ji, Y (2021). Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment. <i>Journal of clinical pharmacology</i> 61(8) 1001–1009. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1825&quot;>10.1002/jcph.1825</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33555033/&quot;>https://pubmed.ncbi.nlm.nih.gov/33555033</a></p></li><li><p>Martínez-Chávez, A, van Hoppe, S, Rosing, H, Lebre, MC, Tibben, M, Beijnen, JH, &amp; Schinkel, AH (2019). P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability. <i>Molecular pharmaceutics</i> 16(9) 3842–3852. DOI:<a href=&quot;https://doi.org/10.1021/acs.molpharmaceut.9b00475&quot;>10.1021/acs.molpharmaceut.9b00475</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31329454/&quot;>https://pubmed.ncbi.nlm.nih.gov/31329454</a></p></li><li><p>Alshogran, OY, Al-Shdefat, R, &amp; Hailat, M (2023). Simple and rapid quantification of ribociclib in rat plasma by protein precipitation and LC-MS/MS: An application to pharmacokinetics of ribociclib nanoparticles in rats. <i>Journal of mass spectrometry : JMS</i> 58(12) e4984–None. DOI:<a href=&quot;https://doi.org/10.1002/jms.4984&quot;>10.1002/jms.4984</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37950646/&quot;>https://pubmed.ncbi.nlm.nih.gov/37950646</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EF02;
